IFN B 1B | NTZ | p-value | |
---|---|---|---|
(n = 9) | (n = 10) | ||
Number of relapses, median (range)^ | 3 | 0 | 0.447 |
- month 1 to 6 | 2 | 0 (0) | |
- month 6 to 12 | 1 | 0 (0) | |
Proportion of relapse free patients over the follow up period (number)° | 78% (7) | 100% (10) | 0.206 |
Annualized relapse rate | |||
- during run-in period NTZ | 0 (0) | 0 (0–1.3) | 0.497 |
EDSS | |||
- at month 6 | 3.0 (1.5-3.5) | 3.0 (1.5-3.5) | 0.966 |
- at month 12 | 3.5 (1.5-3.5) | 3.0 (1.5-3.5) | 0.315 |
Number of new T2 lesions, median (range) ^ | |||
- at month 6 | 1.5 (0–9) | 0 (0–2) | 0.043 |
- at month 12 | 0 (0–12) | 0 (0) | 0.234 |
Number of Gd enhancing lesions, median (range) ^ | |||
- at month 6 | 0 (0–5) | 0 (0) | 0.442 |
- at month 12 | 0 (0–2) | 0 (0–1) | 0.694 |